Effects of Mindfulness Therapy in Patients With Acromegaly and Cushing

Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (Other)
Overall Status
Recruiting
CT.gov ID
NCT04420000
Collaborator
A.O. Ospedale Papa Giovanni XXIII (Other), Consorcio Centro de Investigación Biomédica en Red, M.P. (Other)
120
1
2
13
9.2

Study Details

Study Description

Brief Summary

Randomized, multicenter, international clinical trial (one center in Barcelona and one center in Bergamo, Italy), with exploratory intention.

The main objective of the study will be to assess changes in quality of life, mood, chronic pain and sleep after the delivery of a Mindfulness program.

The secondary objectives will be: to evaluate if this program also affects blood pressure, if the changes are maintained six months after treatment and if it determines the decrease in health resources used.

The intervention group will do Mindfulness sessions according to an established protocol of 8 weeks, while the control group will follow the normal clinical routine. The Mindfulness protocol will be carried out in group sessions led by a therapist with experience in mindfulness and compassion, lasting 120 minutes, weekly, which will take place over 8 weeks.

Two separate studies will be done, one for patients with acromegaly which will be the first to take place and then another for patients with Cushing's syndrome.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mindfulness
  • Other: Control
N/A

Detailed Description

Sixty patients with acromegaly, (30 in Spain and 30 in Italy) and 60 patients with Cushing syndrome (30 in Spain and 30 in Italy), who are visited in the Endocrinology services of the Hospital de la Santa Creu i Sant Pau, Barcelona and Papa Giovanni XXIII in Bergamo will participate in the study.

In each center there will be 30 patients for each pathology (15 will participate in the Mindfulness intervention group and 15 will receive the usual treatment).

Inclusion criteria: 1) age between 18 and 70 years, 2) diagnosis of acromegaly, 3) diagnosis of Cushing's syndrome, 4) patients with controlled disease, 5) not currently participating in any other clinical study.

Exclusion criteria: 1) physical illnesses or comorbidity of serious mental illness that impede the practice of Mindfulness, 2) Patients who for cognitive, neurological or psychiatric reasons could not follow the sessions 3) Patients who do not accept signing the informed consent 4) Patients with Cushing's syndrome or active acromegaly, 5) Simultaneous participation in another clinical study.

Patients who meet the inclusion / exclusion criteria will be invited to participate in the study. The Patient Information Sheet (HIP) and Informed Consent (CI) will be provided. There will be three evaluation visits (pre and post intervention, and 6 months after the intervention) in which the participants must complete different questionnaires and scales. Participants will be invited to keep a daily practice log, and will be required to complete the assigned daily meditation practices for the 8-week program.

Demographic and clinical variables (collected from the medical history) will be included. Patients will also have their blood pressure taken before and after each session.

Questionnaires:
  • Quality of Life: AcroQoL (patients with acromegaly), CushingQoL (patients with Cushing syndrome)

  • Mood: Hospital Anxiety and Depression Scale (HADS)

  • Sleep: Pittsburgh Sleep Quality Index

  • Pain: McGill Pain Questionnaire

  • Self Compassion Scale (SCS)

  • Life satisfaction scale (SWLS)

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Effects of Mindfulness Therapy in Patients With Acromegaly and in Patients With Cushing's Syndrome
Actual Study Start Date :
Sep 1, 2020
Anticipated Primary Completion Date :
Jun 1, 2021
Anticipated Study Completion Date :
Oct 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Interventional group

Patients having a Mindfulness program

Behavioral: Mindfulness
Mindfulness based programme

Placebo Comparator: Control group

Patients having a routinary managment

Other: Control
Treatment as usual

Outcome Measures

Primary Outcome Measures

  1. Change in quality of life in patients with acromegaly [Baseline, post-intervention (8 weeks)]

    using the Acromegaly Quality of Life Questionnaire (AcroQoL)

  2. Change in quality of life in patients with Cushing's syndrome [Baseline, post-intervention (8 weeks)]

    using the Cushing's Quality-of-Life (CushingQOL) questionnaire

Other Outcome Measures

  1. Change in Pain in patients with acromegaly and Cushing's syndrome [Baseline, post-intervention (8 weeks)]

    as evaluated using the McGill Pain Questionnaire

  2. Change in Mood in patients with acromegaly and Cushing's syndrome [Baseline, post-intervention (8 weeks)]

    as evaluate using Hospital Anxiety and Depression Scale (HADS)

  3. Change in Sleep in patients with acromegaly and Cushing's syndrome [Baseline, post-intervention (8 weeks)]

    as evaluate using Pittsburgh sleep scale

  4. Self compassion in patients with acromegaly and Cushing's syndrome [Baseline, post-intervention (8 weeks)]

    as evaluate using Self Compassion Scale (SCS)

  5. Satisfation with life in patients with acromegaly and Cushing's syndrome [Baseline, post-intervention (8 weeks)]

    as evaluate using SWLS questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinical diagnosis of controlled acromegaly,

  • Clinical diagnosis of controlled Cushing syndrome

  • Must be able to perform Mindfulness

Exclusion Criteria:
  • Psychiatric disorders

  • Previous experience with Mindfulness

  • Participation in other clinical trials

Contacts and Locations

Locations

Site City State Country Postal Code
1 Resmini Eugenia Barcelona Spain 08014

Sponsors and Collaborators

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
  • A.O. Ospedale Papa Giovanni XXIII
  • Consorcio Centro de Investigación Biomédica en Red, M.P.

Investigators

  • Principal Investigator: Eugenia Resmini, MD, PhD, Ciberer and IIB Sant Pau

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
ClinicalTrials.gov Identifier:
NCT04420000
Other Study ID Numbers:
  • IIBSP-MIN-2020-16
First Posted:
Jun 9, 2020
Last Update Posted:
Sep 30, 2020
Last Verified:
Sep 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 30, 2020